Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dna X (SONM) EBIT (2018 - 2025)

Dna X (SONM) has disclosed EBIT for 8 consecutive years, with -$4.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT fell 67.51% year-over-year to -$4.0 million, compared with a TTM value of -$32.2 million through Sep 2025, down 151.53%, and an annual FY2024 reading of -$33.6 million, down 6657.31% over the prior year.
  • EBIT was -$4.0 million for Q3 2025 at Dna X, up from -$6.7 million in the prior quarter.
  • Across five years, EBIT topped out at $747000.0 in Q2 2023 and bottomed at -$22.1 million in Q4 2024.
  • Average EBIT over 5 years is -$5.0 million, with a median of -$4.0 million recorded in 2025.
  • The sharpest move saw EBIT soared 135.67% in 2023, then plummeted 1661.27% in 2024.
  • Year by year, EBIT stood at -$11.7 million in 2021, then soared by 90.98% to -$1.1 million in 2022, then fell by 18.51% to -$1.3 million in 2023, then tumbled by 1661.27% to -$22.1 million in 2024, then surged by 81.99% to -$4.0 million in 2025.
  • Business Quant data shows EBIT for SONM at -$4.0 million in Q3 2025, -$6.7 million in Q2 2025, and $645000.0 in Q1 2025.